Primary Care Clinics in Delta, UT Accepting Medicare
3 Primary Care Clinics found. Showing 1 - 3
 White Sage Family Medicine Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 130 White Sage Ave, Delta, UT 84624 Phone: 435-864-2708 |
Scoville Chiropractic Clinic Llp Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 58 E Main St, Suite 1, Delta, UT 84624 Phone: 435-864-5121 |
Delta Family Medicine P.c. Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 140 White Sage Ave, Delta, UT 84624 Phone: 435-864-3333 Fax: 435-864-2790 |
News Archive
CRA appeals to FDA for name change allowance in high fructose corn syrup labeling
In an effort to help clarify the labeling of food products for consumers, the Corn Refiners Association (CRA) today petitioned the U.S. Food and Drug Administration (FDA) to allow manufacturers the option of using 'corn sugar' as an alternative name for high fructose corn syrup.
Lensless cell phone microscope
Cell phones are accumulating a Swiss Army Knife-esqe assortment of capabilities; substituting as cameras, providing internet access, and soon operating as medical labs if Aydogan Ozcan's plans come to fruition. This month's cover article of the journal Lab on a Chip features the latest creation by the Ozcan group, a functioning prototype of a cell phone microscope.
Adamis receives European patent for novel cell-based cancer vaccine technology
Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.
Major campaign victory will create safer environments for children with food allergies
About 11 million people - roughly 1-in-25 Americans - are now believed to be affected by one or more food allergies, a disease triggered by the ingestion or contact with certain foods that may cause life-threatening reactions, or anaphylaxis, according to a recent Food Allergy & Anaphylaxis Network nationwide survey.
Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
› Verified 4 days ago